CAC
ALXN

Cowen and Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Cowen and Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,600
Closed -$151K – 726
2020
Q4 		$151K Buy
31,600
+18,100
+134% +$2.33M 0.01% 194
2020
Q3 		$82K Sell
13,500
-25,300
-65% -$2.73M 0.01% 272
2020
Q2 		$117K Buy
+38,800
New +$4.12M 0.02% 233

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Cowen and Company's ALXN Position: Q3 2021 in Review

Cowen and Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,232 shares — an estimated $3.35M sold.

Cowen and Company first reported a position in ALXN in Q3 2019 and held it in 4 quarters. The position peaked at $3.35M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Cowen and Company reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cowen and Company sold 18,232 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.35M.
  • Cowen and Company first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Cowen and Company's Alexion Pharmaceuticals position peaked at $3.35M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.